AstraZeneca PLC (NASDAQ: AZN) disclosed today that its Imfinzi has received approval for a new dosing option in the US for the treatment of small-cell lung cancer. FDA has granted this option after reviewing the various Imfinzi trials including the CASPIAN Phase III trial and PACIFIC Phase III trial. The patient will be able to access this new treatment weighing 30kg as an alternative to the approved weight-based dosing of 10mg/kg every two weeks.

AZN has earlier received the Priority Review from FDA in August 2020 for Imfizni. This new four-week dosing option gives doctors the opportunity to decrease the number of appointments for critical cancer medication in half and gives a cure that is more beneficial for patients.